Padjadjaran University   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3
Founded: Bandung Indonesia (1957)

Organization Overview

First Clinical Trial
2008
NCT00966628
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Department of Child Health of Medicine Padjadjaran University | Department of Child Health, School of Medicine Padjadjaran University | Department of Obstetrics and Gynecology, Faculty of Medicine, University of Padjadjaran, Hasan Sadikin Hospital, Bandung, Indonesia | Department of Surgery, Dr. Hasan Sadikin Hospital, Bandung, Indonesia | Division of Gastroenterohepatology Department of Internal Medicine Faculty of Medicine, University of Padjajaran Dr. Hasan Sadikin Hospital, Bandung, Indonesia | Dr. Hasan Sadikin General Hospital, Bandung, Indonesia | Dr. Hasan Sadikin Hospital, Bandung | Faculty of Medicine Universitas Padjadjaran | Faculty of Medicine, Universitas Padjadjaran | Faculty of Medicine Universitas Padjadjaran Bandung | Faculty of Medicine Universitas Padjadjaran, Bandung, Indonesia | Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia | Faculty of Medicine Universitas Padjadjaran - Dr. Hasan Sadikin Hospital Bandung | Hasan Sadikin Hospital, Bandung, Indonesia | Hasan Sadikin Hospital, Dept. of Pediatrics, Bandung, Indonesia | Padjadjaran University | Universitas Padjadjaran | University of Padjadjaran

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Dengue (Phase 3)

Gastroesophageal Reflux (Phase 3)

Hepatitis (Phase 1)

Hepatitis A (Phase 1)

Hepatitis B (Phase 1)

Infections (Phase 3)

Meningitis (Phase 3)

Polycystic Ovary Syndrome (Phase 3)

Schizophrenia (Phase 3)

Severe Dengue (Phase 3)

Shock (Phase 3)

Shock, Hemorrhagic (Phase 3)

Syndrome (Phase 3)

Toxoplasmosis (Phase 2)

Toxoplasmosis, Cerebral (Phase 2)

Tuberculosis (Phase 3)

Tuberculosis, Meningeal (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 19
  • # of Trial APIs: 19